GCT-007 CONTINUES TO RECEIVE EXCEPTIONAL GLIOBLASTOMA PRE-CLINICAL RESULTS
For Immediate Release Contact: info@globalcancertechnology.com GCT-007 CONTINUES TO RECEIVE EXCEPTIONAL
CHINA ISSUES GLOBAL CANCER TECHNOLOGY PATENT FOR GCT-007
For Immediate Release Contact: info@globalcancertechnology.com CHINA ISSUES GLOBAL CANCER TECHNOLOGY
DATA SHOWS GCT-007 TO BE COMPARABLE TO PAXALISIB IN INITIAL PRE-CLINICAL STUDIES
For Immediate Release Contact: info@globalcancertechnology.com GLOBAL CANCER TECHNOLOGY REPORTS